VEGF, Basic-FGF, and TGF-β in Crohn's Disease and Ulcerative Colitis : A Novel Mechanism of Chronic Intestinal Inflammation
克罗恩病和溃疡性结肠炎中的 VEGF、Basic-FGF 和 TGF-β:慢性肠道炎症的新机制
基本信息
- 批准号:13671360
- 负责人:
- 金额:$ 1.86万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2001
- 资助国家:日本
- 起止时间:2001 至 2003
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Objective : Inflammatory bowel disease(IBD), the precise etiology of which remains unknown, is comprised of two forms of chronic intestinal inflammation ; ulcerative colitis(UC) and Crohn's disease(CD). Recent evidence increasingly suggests that IBD is the result of dysfunctional immunoregulation manifested by inappropriate production of mucosal cytokines. An abnormal microcirculatory system has also been implicated in its pathogenesis. To elucidate the mechanism of ischemic change in IBD, we assessed serum concentration levels of vascular endothelial growth factor(VEGF) and basic fibroblast growth factor(b-FGF), and plasma level of endothelin-1(ET-1). We also investigated the expression of VEGF, b-FGF, and transforming growth factor-β 1,2,3(TGF-β_<1,2,3>) in tissue by immunostaining.Methods : Blood samples were obtained from 11 patients with UC,11 patients with CD, and 10 patients as controls. Paraffin-embedded samples were used for an immunohistochemicar study.Results : The concentra … More tion levels(in picograms per milliliter) were as follows : for ET-1,UC:127±47.0,CD:167.3±35.1,and controls(asthma:38.5±23.8 p<0.01;diverticulitis:40.5±25.6, p<0.01), for b-FGF,UC:9.2±1.9,CD:9.1±1.5,and controls(asthma:5.0±0,p<0.01;diverticulitis:5.0±0.p<0.01), for VEGF,UC:659.8±181.0,CD:740.0±182.3,and controls(asthma:193.7±58.7,p<0.01;diverticulitis:199.6±59.7,p<0.01). The levels of VEGF and b-FGF were significantly higher in active IBD than those in the controls. There was a significant positive correlation among the serum levels of VEGF and b-FGF, and the plasma level of ET-1;that is, elevated VEGF,b-FGF, and ET-1 levels correlated well with each other. Immunohistochemical studies showed increased venula in the submucosa and lamina propria. Overexpression of VEGF and b-FGF in endothelial cells was revealed and TGF-β_2 and TGF-β_3 were found in inflammatory cells of active IBD, but no change was observed aroud the vessels in the controls.Conclusion : It is suggested that the reciprocal reaction of these cytokines may contribute to angibgenesis in IBD by inducing intestinal ischemia through vasoconstriction. Less
目的:炎症性肠病(IBD),其确切病因仍然未知,由两种形式的慢性肠道炎症组成:溃疡性结肠炎(UC)和克罗恩病(CD)。最近的证据越来越多地表明,IBD是由粘膜细胞因子的不适当产生所表现的免疫调节功能障碍的结果。其发病机制也涉及异常的微循环系统。为了阐明IBD缺血性变化的机制,我们评估了血清血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(b-FGF)的浓度水平,以及血浆内皮素-1(ET-1)的水平。方法:采用免疫组化法检测11例UC患者、11例CD患者和10例正常对照者的外周血中VEGF、b-FGF和转化生长因子-β 1,2,3(TGF-β 1,2,3)的表达。石蜡包埋的样品用于药物化学研究。 ...更多信息 离子水平ET-1组UC为127± 47.0,CD为167.3± 35.1,对照组为127± 47.0,(哮喘:38.5±23.8,p<0.01;憩室炎:40.5±25.6,p<0.01),对于b-FGF,UC:9.2± 1.9,CD:9.1± 1.5,对照组(哮喘:5.0±0,p<0.01;憩室炎:5.0±0.p<0.01),对于VEGF,UC:659.8± 181.0,CD:740.0± 182.3,对照组(哮喘组:193.7± 58.7,p <0.01;憩室炎组:199.6± 59.7,p <0.01)。活动期IBD患者血清VEGF和b-FGF水平明显高于对照组。血清VEGF和b-FGF水平与血浆ET-1水平之间存在显著正相关性;即VEGF、b-FGF和ET-1水平升高彼此相关性良好。免疫组化研究显示,增加微静脉粘膜下层和固有层。结果:IBD活动期血管内皮细胞VEGF、b-FGF表达增强,炎性细胞TGF-β_2、TGF-β_3表达增强,而对照组血管周围无明显变化。结论:IBD时血管内皮细胞VEGF、b-FGF表达增强,炎性细胞TGF-β_2、TGF-β_3表达增强。少
项目成果
期刊论文数量(31)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hideaki Ueno, et al.: "Quantitative detection of carcinoembryonic antigen messenger RNA in the peritoneal cavity of gastric cancer patients by real-time quantitative reverse transcription polymerase chain reaction"Anticancer Res.. 23. 1701-1708 (2003)
Hideaki Ueno等:“通过实时定量逆转录聚合酶链式反应定量检测胃癌患者腹腔内的癌胚抗原信使RNA”Anticancer Res. 23. 1701-1708 (2003)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Atsushi Urakami, Tsukasa Tsunoda, et al.: "Spontaneous fistulization of a pancreatic pseudocyst into the colon and duodenum"Gastrointest Endosc. 55・7. 949-951 (2002)
Atsushi Urakami、Tsukasa Tsunoda 等:“胰腺假性囊肿进入结肠和十二指肠的自发性瘘管”Gastrointest Endosc. 949-951 (2002)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
岩本末治, 角田 司: "消化器ナビゲーター-胆道の手術-"メディカルレビュー社. 4 (2002)
Sueharu Iwamoto、Tsukasa Tsunoda:“胃肠导航器 - 胆道手术”医学评论出版 4 (2002)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kubozoe Tadahiko, Tsunoda Tsukasa, et al.: "Absence of β-catenin gene mutations in pancreatic duct lesions induced by N-nitrosobis (2-oxopropyl) amine in hamsters"Cancer Letters. 168. 1-6 (2001)
Kubozoe Tadahiko、Tsunoda Tsukasa 等人:“仓鼠中 N-亚硝基双(2-氧代丙基)胺诱导的胰管损伤中不存在 β-连环蛋白基因突变”《癌症快报》168. 1-6 (2001)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kazuki Yamashita, et al.: "Three-dimensional computer images of stomach diseases"Am.J.Surg.. 183. 87-88 (2002)
Kazuki Yamashita 等:“胃部疾病的三维计算机图像”Am.J.Surg.. 183. 87-88 (2002)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TSUNODA Tsukasa其他文献
TSUNODA Tsukasa的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TSUNODA Tsukasa', 18)}}的其他基金
Expression of matrix metalloproteinases (MMPs) during hamster pancreatic duct carcinogenesis, detection of serum MMPs in tumor-bearing hamster and chemopreventive effect of hamster pancreatic cancer
基质金属蛋白酶(MMPs)在仓鼠胰管癌变过程中的表达、荷瘤地鼠血清MMPs的检测及对仓鼠胰腺癌的化学预防作用
- 批准号:
11671291 - 财政年份:1999
- 资助金额:
$ 1.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Studies on islet cell viability atored with various preservatives : Assessment of adynylylcyclase activity as a marker for islet cell viability
用各种防腐剂对胰岛细胞活力的研究:评估作为胰岛细胞活力标记的腺苷酰环化酶活性
- 批准号:
07457283 - 财政年份:1995
- 资助金额:
$ 1.86万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Experimental and Clinical Studies on Transplantation of the Pancreas
胰腺移植的实验与临床研究
- 批准号:
60480304 - 财政年份:1985
- 资助金额:
$ 1.86万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)
相似海外基金
Preclinical validation of small molecule immunomodulators for the treatment of Crohn's disease
小分子免疫调节剂治疗克罗恩病的临床前验证
- 批准号:
10600659 - 财政年份:2023
- 资助金额:
$ 1.86万 - 项目类别:
Application of social cognitive theory to physical activity behavior among adults with Crohn's disease
社会认知理论在克罗恩病成人体力活动行为中的应用
- 批准号:
10745823 - 财政年份:2023
- 资助金额:
$ 1.86万 - 项目类别:
Predicting Clinical Phenotypes in Crohn's Disease Using Machine Learning and Single-Cell 'omics
使用机器学习和单细胞组学预测克罗恩病的临床表型
- 批准号:
10586795 - 财政年份:2023
- 资助金额:
$ 1.86万 - 项目类别:
The Interplay of Host Genetic Variation and the Gut Microbiome in Crohn's Disease
克罗恩病宿主遗传变异与肠道微生物组的相互作用
- 批准号:
10751276 - 财政年份:2023
- 资助金额:
$ 1.86万 - 项目类别:
New insights into the development of metabolic dysfunction as a comorbidity in Crohn's disease.
关于代谢功能障碍作为克罗恩病合并症的发展的新见解。
- 批准号:
493720 - 财政年份:2023
- 资助金额:
$ 1.86万 - 项目类别:
Operating Grants
Fibrosis Associated Protein Inhibitor (FAPI) radiotracer-based imaging to identify fibrosis activity in intestinal Crohn's Disease (FATE-CD)
基于纤维化相关蛋白抑制剂 (FAPI) 的放射性示踪成像,可识别肠道克罗恩病 (FATE-CD) 中的纤维化活动
- 批准号:
MR/X030784/1 - 财政年份:2023
- 资助金额:
$ 1.86万 - 项目类别:
Research Grant
Sex Differences in Statural Growth Impairment in Pediatric Crohn's Disease: Part 2
儿童克罗恩病身高发育障碍的性别差异:第 2 部分
- 批准号:
10638422 - 财政年份:2023
- 资助金额:
$ 1.86万 - 项目类别:
Deconstructing the fibrotic microenvironment in Crohn's disease to promote tissue healing
解构克罗恩病的纤维化微环境,促进组织愈合
- 批准号:
MR/X008789/1 - 财政年份:2023
- 资助金额:
$ 1.86万 - 项目类别:
Research Grant
Significance of endoscopic quantitative evaluation of small bowel stricture in patients with Crohn's disease and elucidation of restenosis factors after balloon dilatation
内镜定量评估克罗恩病患者小肠狭窄的意义及阐明球囊扩张后再狭窄因素
- 批准号:
23K07446 - 财政年份:2023
- 资助金额:
$ 1.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Blood Protein Markers of Biologic Treatment Response in Crohn's Disease
克罗恩病生物治疗反应的血液蛋白标志物
- 批准号:
10666986 - 财政年份:2023
- 资助金额:
$ 1.86万 - 项目类别: